INTRODUCTION
Obesity is a major risk factor for type 2 diabetes, insulin resistance, and cardiovascular disease (1;2).
There is increasing evidence that these disorders are characterized by enhanced inflammatory activity (3) (4) (5) (6) . Obese adipose tissue produces increased amounts of inflammatory cytokines, such as TNF-α (3;7), IL-6 (8), TGF-β (9), and iNOS (10) . These have been implicated in the pathogenesis of insulin resistance and cardiovascular disease (3;4;6;11) . Recent studies have shown that obese adipose tissue exhibits increased infiltration by macrophages, and moreover, that macrophages may be a primary source of proinflammatory factors (12) (13) (14) .
Thus, macrophage infiltration into adipose tissue may be an important contributor to the enhanced inflammatory activity in obesity.
A factor that may be important for macrophage infiltration into fat is the chemokine, CC chemokine ligand 2 (CCL2 or monocyte chemoattractant protein-1). CCL2 is crucial for macrophage recruitment in several inflammatory states (15) (16) (17) (18) (19) . Moreover, its levels in adipose tissue and plasma are highly elevated in obesity (20) (21) (22) (23) . Recent studies have shown that obese mice deficient in CCL2 (24) or its receptor, CCR2 (25) , have decreased adipose tissue macrophage infiltration and improved metabolic function. Conversely, mice overexpressing CCL2 in fat show the opposite phenotype (24;26) . In the current study, we also examined CCL2-/-mice to study the role of CCL2 in macrophage recruitment and metabolic function. Surprisingly, CCL2-/-mice on high fat diet did not show any reductions in adipose tissue macrophages. Moreover, CCL2 absence in mice on standard and high fat diets did not improve metabolic control, and even appeared to worsen it. Thus, CCL2 does not appear to be critical for macrophage recruitment in obesity, and may have effects on metabolism that are independent of its macrophage-recruiting capabilities.
METHODS

Animals
Male CCL2-/-and wildtype mice on a C57BL/6J background (The Jackson Laboratory, Bar Harbor, ME) were housed 2-4 per cage and maintained on a 14:10 h light:dark cycle. Six week-old mice (n = 11-14/group) were placed on standard (Rodent Diet 8664, 4.05 kcal/g, 17.4% kcal fat, Harlan Teklad, Madison, WI) or high fat (HFD; D12331, 5.56 kcal/g, 58% kcal fat, Research Diets, New Brunswick, NJ) diet. All groups, regardless of diet, had the same caloric intake (~14 kcal/day). At 12 weeks of age, fasting glucose, insulin, leptin, and adiponectin levels were measured. The same animals then underwent glucose tolerance tests (GTT) at 14 weeks (1.5mg/g body weight glucose, i.p., after overnight fast) and insulin tolerance tests (ITT) at 16 weeks (1mU/g body weight, i.p., after 4h fast; Humulin R, Eli Lilly, Indianapolis, IN).
Fasting glucose and hormones, GTTs, and ITTs were again performed at 25, 27, and 29 weeks of age, respectively. Insulin sensitivity was also assessed by homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated by multiplying fasting insulin levels (µL/mL) by fasting glucose levels (mM) divided by 22.5. At 23 weeks, body fat composition was determined by dual energy x-ray absorptiometry (DEXA; MEC Lunar Corp., Minster, OH). All procedures were approved by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee.
Adipose tissue collection
Thirty four week old mice were euthanized by CO 2 inhalation and fat depots were collected.
For perigonadal and subcutaneous fat, 0.4-1.2g was placed in Krebs Ringer HEPES (KRH) buffer containing 10mg/mL fatty acid-poor BSA (Sigma-Aldrich, St. Louis, MI) for isolation of adipocytes and stromal vascular cells (SVCs). A portion of perigonadal fat was snap-frozen for RNA analysis. Perigonadal and subcutaneous fat were also placed in zinc formalin fixative for immunohistochemical analysis.
Isolation of adipocytes and SVCs from adipose tissue
Adipose tissue in KRH buffer was minced and centrifuged to remove blood cells. It was then digested in 0.12units/mL of lowendotoxin collagenase (Liberase 3; Roche Applied Science, Indianapolis, IN) by shaking (80Hz) at 37°C for 45 min. Samples were filtered through 300µm nylon mesh (Spectrum Laboratories Inc., Rancho Dominguez, CA) and the resulting suspension was centrifuged at 500g for 10 min to separate SVCs from adipocytes. Adipocytes were stored in phenol-guanidine thiocyanate reagent (Qiagen Inc., Valencia, CA) at -80°C for subsequent RNA isolation. SVCs were incubated in erythrocyte lysis buffer (0.154mM NH 4 Cl, 10mM KHCO 3 , 0.1mM EDTA) for 2 min and then washed with KRH-BSA. Cells were then suspended in fluorescence activated cell sorting (FACS) buffer (PBS with 5mM EDTA and 0.2% fatty acid-poor BSA). A portion of the cells was counted with a hemacytometer. Based on trypan blue exclusion, the percentage of live cells per sample was 70 ± 3% and 70 ± 2% for perigonadal and subcutaneous SVCs, respectively. The remaining SVCs underwent FACS analysis, as described below.
Determination of adipose tissue macrophage levels and isolation of macrophages from SVCs by FACS
SVCs were incubated in the dark on a shaker with FcBlock (20µg/mL; BD Pharmingen, San Jose, CA) for 30 min at 4°C. Perigonadal SVCs were incubated for 50 min with APC-conjugated F4/80 antibody (5µg/mL) and PE-conjugated CD11b (Mac 1) antibody (2µg/mL; Caltag Laboratories Inc., Burlingame, CA), both cell surface markers of mature macrophages that are not detected on preadipocytes (27;28) . Subcutaneous SVCs were incubated only with F4/80 antibody.
After For perigonadal SVCs, we used the combined percentage of F4/80 +, CD11b +, and F4/80/CD11b +/+ cells to determine the number of macrophages in perigonadal adipose tissue.
RT-PCR on adipose tissue, adipocyte, and SVC RNA Total RNA was isolated from whole perigonadal adipose tissue, adipocytes, F4/80/CD11b +/+ cells, and F4/80/CD11b -/-cells, and then reverse-transcribed to cDNA (Retroscipt, Ambion, Inc. Austin, TX). TaqMan (Applied Biosystems, Branchburg, NJ) RT PCR was then performed for measurement of mRNA for the macrophage markers, F4/80, CD11b, and CD68, as well as TNF-α, IL-6, IL-1β, IL-10, iNOS, SOCS-3, and hypoxia-inducible factor 1-α (HIF-1α). Relative expression levels of the mRNAs were determined using standard curves. Samples were adjusted for total RNA content by comparison with cyclophilin or 18S expression. TNF-α, IL-1β, iNOS, SOCS-3, cyclophilin, and 18S primer (Invitrogen Corp., Carlsbad, CA) and probe (Biosearch Technologies, Inc., Novato, CA) sequences can be provided upon request. For the remaining genes, primer-probe mixtures from Applied Biosystems were used.
Adipose tissue immunohistochemistry
Paraffin sections of adipose tissue were analyzed for macrophage content by staining with antibody against F4/80. Sections underwent trypsin antigen retrieval, followed by blocking with avidin, biotin (Vector Laboratories, Burlingame, CA), and rabbit serum. Sections were then incubated with rat anti-mouse F4/80 antibody (1:75; Serotec, Raleigh, NC) overnight at 4°C. F4/80 staining was detected by incubating the slides with biotinylated rabbit anti-rat antibody, followed by treatment with peroxidase-conjugated streptavidin (Vector Laboratories) and 3-amino-9-ethylcarbazole (Dako Corp., Carpinteria, CA). Slides were counterstained with hematoxylin. For determination of macrophage infiltration, two 10X-magnified fields from each of two adipose sections per mouse were analyzed. The percentage of macrophages was determined by counting the number of nuclei of F4/80-positive cells relative to the total number of cell nuclei per field.
Serum and plasma measurements
Serum insulin (CrystalChem, Downers Grove, IL), leptin (CrystalChem), adiponectin (Linco Research, St. Charles, MO), and CCL7 (Bender MedSystems Inc., Burlingame, CA) concentrations were determined by ELISA. Serum CCL2 levels were measured with the Mouse Serum Adipokine LincoPlex Kit by Linco Research. Plasma glucose levels were measured with a glucometer (Lifescan Inc., Milpitas, CA).
Statistical analysis
Data are presented as mean ± SEM. Measurements were analyzed by one-way ANOVA followed by Duncan's post-hoc test for multiple comparisons. Significance was set at P<0.05.
Statistical analysis was performed with Statistica software (Statsoft, Inc., Tulsa, OK).
RESULTS
Serum CCL2 and CCL7 levels are increased in wildtype mice on HFD, but are undetectable in CCL2 -/-mice
Wildtype mice on HFD had markedly increased (P<0.001) serum CCL2 levels compared with mice on standard diet (Std diet: 39 ± 11 pg/mL, n=9; HFD: 167 ± 34 pg/mL, n=9). CCL2 was very low or undetectable in CCL2-/-mice on either diet (Std diet: 0 pg/mL, n=8; HFD: 4.0 ± 4.0 pg/mL, n=9).
To rule out whether compensatory increases in other CCR2 ligands might be occurring in CCL2-/-mice, we measured serum levels of another CCR2 ligand, CCL7 (MCP-3). CCL7 was also increased (P<0.001) in HFD-fed wildtype mice (Std diet: 1.3 ± 0.7 pg/mL, n=11; HFD: 15.7 ± 4.3 pg/mL, n=11). Surprisingly, CCL7 was also undetectable in CCL2-/-mice (Std diet: 0 pg/mL, n=10; HFD: 0 pg/mL, n=12), suggesting that CCL7 levels may be regulated by CCL2.
CCL2-/-mice show mildly enhanced weight gain in response to HFD compared to wildtype mice
Unexpectedly, CCL2-/-mice gained more weight on HFD than wildtype mice (P<0.05; Fig 1a) . From 18 to 34 weeks of age, CCL2-/-mice weighed on average 13% more than HFD-fed wildtype mice. This was associated with 15% increases in percent body fat and fat pad weights, and elevated serum leptin levels (P<0.05; Fig 1c-e) . Lean mass was unaltered (data not shown). CCL2-/-mice on standard diet weighed slightly less than wildtypes (P<0.05 at some ages; Fig 1b) . However, there were no differences in body fat, serum leptin, and lean mass. Food intake for CCL2-/-mice on HFD and standard diet did not differ from wildtypes (data not shown).
Absence of CCL2 does not limit macrophage infiltration into adipose tissue
Immunohistochemical analysis of perigonadal adipose tissue stained with antibody against the macrophage marker, F4/80, showed that HFD in wildtype mice induced a 5-fold increase in the percentage of macrophages (Fig 2a,c,e) . Messenger RNA levels of the macrophage markers, F4/80, CD11b, and CD68 were also increased (P<0.05) following HFD (Table 1) . By FACS, there was a small increase (P<0.05) in the percentage of macrophages within the SVF (Fig 2f) , and a 5-fold increase (P<0.05) in macrophage numbers per depot in HFD mice (Fig 2g) .
Surprisingly, HFD-fed CCL2-/-mice did not show any reductions in the percentage of macrophages in adipose tissue stained for F4/80 (Fig 2d,e) . There was even a very mild, but significant (P<0.05), increase in the percentage of macrophages. F4/80, CD11b, and CD68 mRNA levels also did not differ from wildtype mice ( Table 1) . By FACS, the percentage of macrophages within the SVF was similar to wildtype mice (Fig 2f) .
Macrophage numbers per depot were also mildly increased (P<0.05, Fig 2g) . This may in part have been due to the increased size of the perigonadal depot in CCL2-/-mice on HFD. Thus, in the present study, absence of CCL2 did not decrease obesity-associated infiltration of macrophages into adipose tissue. In CCL2-/-mice on standard diet, macrophage numbers and macrophage marker mRNA levels also did not differ from wildtypes (Fig 2b,e-g, Table 1 ). Macrophage numbers were also unaltered in subcutaneous fat of CCL2-/-mice (not shown).
CCL2 absence does not improve metabolic function
CCL2 absence did not improve metabolic function in CCL2-/-mice fed either diet. Unexpectedly, metabolic control even appeared to be slightly worsened in CCL2-/-mice. At 14 and 27 weeks of age, CCL2-/-mice on both diets were glucose intolerant compared with wildtypes (P<0.05, Figs 3a-d) . The glucose intolerance grew worse with age in CCL2-/-mice on standard diet. At 27 weeks, peak glucose levels in standard dietfed CCL2-/-mice were 6mM higher than in wildtypes. For HFD fed mice, the difference in glucose tolerance at 27 weeks was smaller than at 14 weeks, due to the worsened glucose tolerance of wildtypes. CCL2-/-mice on standard and HFD also showed mild increases (P<0.05) in fasting glucose, and decreases (P<0.05) in serum adiponectin (Figs 3e,f) . Fasting insulin levels and HOMA-IR values in 25 week-old HFD CCL2-/-mice were nearly double of wildtype levels (P<0.05; Figs 4a,b), suggesting that CCL2 absence worsened obesity-associated insulin resistance.
However, these results are inconclusive, since insulin sensitivity as assessed by ITT did not appear to differ (Figs  4c,d ).
CCL2 absence does not alter inflammatory marker mRNA expression in whole adipose tissue
We also investigated the effect of obesity and CCL2 absence on adipose tissue inflammatory marker mRNA.
As with macrophage marker mRNA, perigonadal TNF-α mRNA levels were both low in wildtype and CCL2-/-mice on standard diet, and increased similarly in response to HFD (Wildtype Std Diet: 0.45 ± 0.03, n=12; CCL2-/-Std Diet: 0.42 ± 0.04, n=10; Wildtype HFD: 0.95 ± 0.07, n=12; CCL2-/-HFD: 1.03 ± 0.06, n=10; TNF/cyclophilin expression; P<0.001 vs. Std Diet). In wildtype and CCL2-/-mice, HFD also led to similar increases in CCR2 mRNA, indicating that CCL2 absence did not lead to compensatory increases in expression of its receptor (Wildtype Std Diet: 0.62 ± 0.04, n=12; CCL2-/-Std Diet: 0.49 ± 0.02, n=11; Wildtype HFD: 0.86 ± 0.06, n=12; CCL2-/-HFD: 0.79 ± 0.06, n=12; CCR2/cyclophilin expression; P < 0.05, HFD vs. Std Diet). This finding, combined with the reduced serum CCL7 levels in CCL2-/-mice, suggests that the phenotype of CCL2-/-mice was unlikely due to increased signaling by other CCR2 ligands. There were no effects of HFD or CCL2 absence on IL-6, IL-1β, iNOS, and SOCS-3 mRNA levels (not shown).
Absence of CCL2 alters inflammatory gene expression in adipose tissue cells
We also examined the effects of HFD and CCL2 absence on expression of inflammatory markers in adipocytes, and macrophages (F4/80 and CD11b +/+ cells) and non-macrophage SVCs (F4/80 and CD11b -/-cells) isolated by FACS. In wildtype mice on standard diet, F4/80 mRNA was primarily restricted to the macrophage fraction (Fig 5a) . TNF-α, IL-1β, and IL-10 mRNA were also highest (P<0.05) in the macrophages (Figs 5b-d Messenger RNA for HIF-1α, a controller of the cellular response to hypoxia that is increased in adipose tissue of obese humans (13), was increased (P<0.05) in nonmacrophage SVCs, but decreased (P<0.05) in adipocytes in response to HFD (Fig 5g) .
CCL2-/-mice on standard diet had higher (P<0.05) TNF-α and IL-10 mRNA levels across all cell populations than their wildtype counterparts. There was higher (P<0.05) IL-1β mRNA expression in adipocytes and non-macrophage SVCs, and higher (P<0.05) IL-6 and HIF-1α mRNA in adipocytes, but lower (P<0.05) SOCS-3 mRNA in adipocytes. Although these data contrast with the similar inflammatory gene mRNA levels in whole adipose tissue, they suggest that there may have been some enhancement of inflammatory activity in adipose tissue of CCL2-/-mice on standard diet. In HFD fed mice, CCL2 deficiency enhanced (P<0.05) the obesity-associated increases in macrophage F4/80 and SOCS-3 mRNA, and non-macrophage SVC IL-10 and HIF-1α mRNA. However, adipocyte TNF-α and IL-1β mRNA levels in HFD CCL2-/-mice were lower (P<0.05) than in wildtypes. Adipocyte F4/80 mRNA was also lower, suggesting that the decreased TNF-α and IL-1β mRNA levels may have been due to the presence of fewer residual macrophages in the adipocyte fraction.
DISCUSSION
Obesity is associated with increased macrophage infiltration of adipose tissue (12-14;22;29) . Moreover, there is evidence to suggest that macrophages may be largely responsible for the enhanced inflammatory activity of obese adipose tissue (12;22) . The mechanisms underlying macrophage recruitment to adipose tissue are not known. The chemokine, CCL2 is a critical chemoattractant for macrophages in several inflammatory models (15) (16) (17) (18) (19) . In obesity, levels of CCL2 in serum and adipose tissue are markedly increased (20) (21) (22) (23) , suggesting that CCL2 may be an important macrophagerecruiting factor.
We studied mice deficient in CCL2 to examine the role of CCL2 in macrophage recruitment and metabolic function. Surprisingly, despite having nearly undetectable serum CCL2 levels, immunohistochemical and FACS analysis of adipose tissue showed that CCL2-/-mice on standard and high fat diets did not have reduced macrophage numbers compared to wildtype mice.
RT-PCR also showed identical increases in adipose tissue gene expression of the macrophage markers, F4/80, CD11b, and CD68 in CCL2-/-and wildtype mice following HFD. Our results contrast with the recent reports of reduced adipose tissue macrophages in obese CCL2-/- (24) and CCR2-/-(25) C57BL/6J mice. Notably, however, the reductions in macrophage numbers in these studies were small. By immunohistochemistry, the fraction of macrophages in perigonadal fat was only decreased by 20-30% (24;25) . Furthermore, another study in HFD-fed CCR2-/-mice on a DBA1/J background showed no decreases in adipose tissue macrophages (30) . At the time of tissue collection, our mice were only a few weeks older than the previously studied CCL2-/-and CCR2-/-mice (24;25). Thus, it is unlikely that the fact we collected adipose tissue at 34 weeks of age was the reason for the lack of reductions in macrophages in our mice.
Transgenic mice over-expressing CCL2 in adipose tissue have also been studied (24;26) . In one study, CCL2 transgenic mice had nearly double the serum CCL2 levels seen in wildtype mice on HFD, but 40% fewer macrophages in fat (24) . Other CCL2 transgenic mice had 2.5-fold higher plasma CCL2 levels than wildtypes, but only 25% more macrophages (26) . These and our data suggest that CCL2 may not be the primary macrophage-recruiting factor in obese adipose tissue. Although mice lacking CCL2 exhibit reduced macrophage infiltration in several models of inflammation (16) (17) (18) (19) , there are circumstances in which CCL2 is elevated, but does not contribute to macrophage recruitment (31;32).
For example, macrophage infiltration into skin incision wounds is not reduced in CCL2-/-mice, despite the fact that CCL2 levels at wound sites are high in normal animals (31) . Given the mild effects of CCL2 absence on adipose tissue macrophages in the previous studies, it is possible that differences in experimental conditions contributed to the discrepancies in our findings. In the earlier study, CCL2-/-and wildtype mice were from different sources (24), whereas our CCL2-/-mice had been backcrossed with the wildtype controls. Variations in genetic background may have contributed to the differences between wildtype and CCL2-/-mice in the earlier study. With regards to the CCR2-/-mice, it cannot be ruled out that the phenotype in CCR2-/-mice was also due to decreased action of the other CCR2 ligands, CCL7 (MCP-3) (33), CCL8 (MCP-2) (34), CCL12 (MCP-5) (35) , and CCL13 (MCP-4) (36).
CCL2 absence did not improve metabolic function, and unexpectedly, seemed to slightly worsen it. CCL2-/-mice on HFD had slightly increased body fat and higher serum insulin levels than wildtype mice. The increased adiposity may have been an effect of CCL2 absence to enhance adipose tissue growth. Interestingly, the obese CCR2-/-mice studied previously had larger adipocytes (25) . Earlier reports also showed that CCL2 induces adipocyte dedifferentiation in 3T3-L1 adipocytes, by reducing triglyceride content and expression of genes expressed in mature adipocytes, such as LpL, adipsin, GLUT-4, aP2, β3-adrenergic receptor, and PPAR-γ (23;37) . Surprisingly, CCL2-/-mice on HFD and standard diet were also glucose intolerant and had mildly increased glucose levels. Given that macrophage numbers were unchanged, this phenotype appears to have been due to absence of CCL2 itself. Previous studies showed unaltered metabolic function in lean CCL2-/-and CCR2-/-mice and improved glucose tolerance and insulin sensitivity in CCL2-/-and CCR2-/-mice on HFD (24;25). As mentioned above, these differences from our data may have been related to background variations in the CCL2-/-and wildtype mice used in the earlier study, and loss of action of other CCR2 ligands in CCR2-/-mice. Nonetheless, our findings also contrast with the glucose intolerance and insulin resistance seen in mice overexpressing CCL2 in fat under the ap2 promoter (24;26) .
The reason for the worsened metabolic regulation in our animals is not known. It should be noted, however, that deficiency of CCL2 has complex effects on immune function, causing both upregulation and downregulation of inflammatory factors (32;38;39) . In endotoxin-treated mice, neutralization of CCL2 increases serum TNF-α and IL-12 levels (39), and in CCL2-/-or CCL2-neutralized mice, others have found higher levels of TNF-α and IL-10 (32;38). In our isolated adipocytes, macrophages, and nonmacrophage SVCs from adipose tissue of lean and obese CCL2-/-mice, there was some enhancement of inflammatory gene expression. While this did not translate into increased inflammatory gene expression in the whole tissue, we cannot rule out that increased inflammatory activity in fat or elsewhere could have contributed to the defects in our mice.
Since CCR2 has several ligands, we explored whether the metabolic defects in our CCL2-/-mice were due to compensatory increases in other chemokines that act at CCR2, or increases in CCR2 itself. We did not observe any increases in serum CCL7 or adipose tissue CCR2 mRNA in CCL2-/-mice. In fact, serum CCL7 was undetectable in these animals. In agreement, a previous study in CCL2-/-mice reported 50% decreases in kidney levels of CCL7 and CCL12 mRNA (19) . The decrease in CCL7 expression does not appear to be due to inadvertent targeting of CCL7 during the generation of CCL2-/-mice (16) . Thus, the worsened metabolic control in CCL2-/-mice was not likely due to compensatory increases in CCL7 and other CCR2 ligands, or enhanced sensitivity to these ligands due to increased CCR2 expression.
In addition to examining the role of CCL2 in obesity-associated macrophage recruitment, we examined the contributions of different adipose tissue cell populations to the inflammatory activity of adipose tissue. Recent data has suggested that macrophages are the primary source of adipose tissue inflammatory cytokines, such as TNF-α and iNOS (12) . In mice on standard diet, we found that TNF-α, IL-1β, and IL-10 mRNA were most prominently expressed in the macrophage fraction, suggesting that macrophages may be the primary source of these cytokines. Conversely, SOCS-3 mRNA was highest in adipocytes, while IL-6 mRNA was lowest in macrophages. Obesity increased IL-1β mRNA in adipocytes, and IL-10 and IL-1β mRNA non-macrophage SVCs. TNF-α and IL-10 mRNA were increased in adipocytes, but it is unclear whether this was due to the presence of residual macrophages. IL-6, SOCS-3, and HIF-1α mRNA, were increased in some populations, but decreased in others. Overall, our data suggest that enhanced inflammatory activity in adipose tissue is not only due to increased macrophage infiltration, but also inflammatory activation of adipose tissue cells.
In summary, we report that absence of CCL2 does not attenuate obesity-associated macrophage recruitment into adipose tissue or improve metabolic function. In this study, CCL2 absence appeared to even slightly worsen obesity and cause mild metabolic dysregulation, even in mice fed low fat diets, indicating that CCL2 has effects on metabolism that are independent of its macrophage-recruiting capabilities. Based on these data and the previous reports showing little or no effect of CCL2 or CCR2 absence to reduce adipose tissue macrophages in obesity (24;25;30), we conclude that CCL2 is not critical for obesity-associated macrophage recruitment to adipose tissue. The dominant factor for drawing macrophages into adipose tissue in obesity therefore remains to be identified. 
